It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A mild decrease of ADAMTS13 (a disintegrin and metalloprotease with thrombospodin type 1 motif 13) could attribute to stroke and coronary heart disease in general population. However, the role of ADAMTS13 in hemodialysis (HD) patients remains to be explored. This cross-sectional and observational cohort study enrolled 98 chronic HD patients and 100 normal subjects with the aims to compare the ADAMTS13 activity between chronic HD patients and normal subjects, and to discover the role of ADAMTS13 on the newly developed cardiovascular events for HD patients in a 2-year follow-up. Our HD patients had a significantly lower ADAMTS13 activity than normal subjects, 41.0 ± 22.8% versus 102.3 ± 17.7%, p < 0.001. ADAMTS13 activity was positively correlated with diabetes, triglyceride and hemoglobin A1c, and negatively with high-density lipoprotein cholesterol levels in HD patients. With a follow-up of 20.3 ± 7.3 months, the Cox proportional hazards model revealed that low ADAMTS13, comorbid diabetes, and coronary heart diseases have independent correlations with the development of cardiovascular events. Our study demonstrated that chronic HD patients have a markedly decreased ADAMTS13 activity than normal subjects. Although ADAMTS13 seems to correlate well with diabetes, high triglyceride and low high-density lipoprotein cholesterol levels, ADAMTS13 deficiency still carries an independent risk for cardiovascular events in chronic HD patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 I-Shou University, School of Medicine for International Students, College of Medicine, Kaohsiung, Taiwan (GRID:grid.411447.3) (ISNI:0000 0004 0637 1806); E-DA Hospital, Division of Nephrology, Department of Internal Medicine, Kaohsiung City, Taiwan (GRID:grid.414686.9) (ISNI:0000 0004 1797 2180)
2 I-Shou University, Department of Medical Laboratory Science, Kaohsiung, Taiwan (GRID:grid.411447.3) (ISNI:0000 0004 0637 1806); E-DA Hospital, Department of Medical Research, Kaohsiung, Taiwan (GRID:grid.414686.9) (ISNI:0000 0004 1797 2180)
3 E-DA Hospital, Division of Nephrology, Department of Internal Medicine, Kaohsiung City, Taiwan (GRID:grid.414686.9) (ISNI:0000 0004 1797 2180); Hsin-Jen Hospital, Division of Nephrology, Department of Internal Medicine, New Taipei City, Taiwan (GRID:grid.414686.9)
4 E-DA Hospital, Division of Nephrology, Department of Internal Medicine, Kaohsiung City, Taiwan (GRID:grid.414686.9) (ISNI:0000 0004 1797 2180)
5 E-DA Hospital, Department of Laboratory Medicine, Kaohsiung, Taiwan (GRID:grid.414686.9) (ISNI:0000 0004 1797 2180)